title: A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma.
abstract: The present study aims to assess the feasibility and the effectiveness of a second-line Fotemustine chemotherapy in patients with recurrent Glioblastoma after standard primary treatment. Between 2005 and 2007, 50 patients with relapsed malignant glioma (median age=56.8 years; median KPS=90) underwent a second-line chemotherapy with Fotemustine. Selected patients were previously treated with a standard 60 Gy Radiotherapy course and Temozolomide Chemotherapy. Patients were stratified into classes according to the prognostic Recursive Partition Analysis. Endpoints of the study were Progression Free Survival at 6 months, duration of Objective Response and Stabilization, Overall Survival and toxicity. At analysis, 36 patients were dead and 14 were alive. Median follow-up from primary diagnosis was 26.6 months. The Efficacy control of the disease was 62%. PFS was 6.1 months; PFS-6 was 52% and median overall survival from primary diagnosis was 24.5 months, with few manageable haematological toxicities. Fotemustine was safe and effective as second-line chemotherapy in recurrent glioblastoma.
authors.affiliation: Radiotherapy Division of Pisa University Hospital, Pisa, Italy. m.fabrini@ao-pisa.toscana.it
authors.forename: Maria Grazia
authors.initials: MG
authors.lastname: Fabrini
authors.forename: Giovanni
authors.initials: G
authors.lastname: Silvano
authors.forename: Ivan
authors.initials: I
authors.lastname: Lolli
authors.forename: Franco
authors.initials: F
authors.lastname: Perrone
authors.forename: Annarita
authors.initials: A
authors.lastname: Marsella
authors.forename: Valerio
authors.initials: V
authors.lastname: Scotti
authors.forename: Luca
authors.initials: L
authors.lastname: Cionini
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000401:mortality; D018572:Disease-Free Survival; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D009943:Organophosphorus Compounds / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; D009943:Organophosphorus Compounds; C054368:fotemustine